Halozyme Therapeutics (HALO) Gains from Investment Securities (2010 - 2026)
Halozyme Therapeutics (HALO) reported Gains from Investment Securities of $170000.0 for Q1 2026, up 78.95% year-over-year from $95000.0 in Q1 2025, and up 106.49% quarter-over-quarter from -$2.6 million in Q4 2025.
Halozyme Therapeutics (HALO) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 16 years of Gains from Investment Securities data on file, last reported at $170000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $170000.0, up 78.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.5 million (down 231.85% YoY), and the FY2025 annual result was -$2.6 million, down 185.15% from the prior year.
- Gains from Investment Securities climbed to $170000.0 in Q1 2026 per HALO's latest filing, from -$2.6 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $16.3 million in Q4 2022 and troughed at -$3.1 million in Q3 2024.
- A 5-year average of $1.2 million and a median of $220500.0 in 2022 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 249.45% in 2024 and fell as far as 1906.9% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $16.3 million in 2022, then slumped by 91.65% to $1.4 million in 2023, then surged by 249.45% to $4.8 million in 2024, then plunged by 155.11% to -$2.6 million in 2025, then surged by 106.49% to $170000.0 in 2026.
- Business Quant data shows HALO's Gains from Investment Securities at $170000.0 in Q1 2026, -$2.6 million in Q4 2025, and -$732000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 170,000.00 |
| Mar 31, 2026 | 170,000.00 |
| Dec 31, 2025 | -2.62 Mn |
| Dec 31, 2025 | -2.62 Mn |
| Sep 30, 2025 | -732,000.00 |
| Sep 30, 2025 | -732,000.00 |
| Jun 30, 2025 | 637,000.00 |
| Jun 30, 2025 | 637,000.00 |
| Mar 31, 2025 | 95,000.00 |
| Mar 31, 2025 | 95,000.00 |
| Dec 31, 2024 | 4.76 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Sep 30, 2024 | -3.14 Mn |
| Sep 30, 2024 | -3.14 Mn |
| Jun 30, 2024 | 224,000.00 |
| Jun 30, 2024 | 224,000.00 |
| Mar 31, 2024 | 1.24 Mn |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Dec 31, 2023 | 1.36 Mn |